Do dual nucleoside regimens have a role in an era of plasma viral load- driven antiretroviral therapy?

Journal of Infectious Diseases

Volumn 178, Issue 3, 1998, Pages 662-668

  Rhone, Stephanie A ^b   Hogg, Robert S ^b   Yip, Benita ^b   Sherlock, Chris ^b   Conway, Brian ^b   Schechter, Martin T ^b   O'Shaughnessy, Michael V ^b   Montaner, Julio S G ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE; NUCLEOSIDE ANALOG; STAVUDINE; ZIDOVUDINE;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; DRUG EFFECT; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VIRUS LOAD; VIRUS REPLICATION;

EID: 0031656026     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/515365     Document Type: Article

References (15)

1. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for 1997: updated recommendations of an international panel. JAMA 1997;277:1962-9.
2. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of 2 nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997;337:725-33.
3. Montaner JSG, Hogg RS, O'Shaughnessy MV. Emerging international consensus for the use of antiretroviral therapy. Lancet 1997;349:1042.
4. + cells per cubic millimeter. N Engl J Med 1995;333:1662-9.
5. CAESAR Coordinating Committee. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet 1997;349:1413-21.
6. Pollard R, Peterson D, Hardy D, et al. Antiviral effect and safety of stavudine and didanosine combination therapy in HIV-infected subjects in an ongoing pilot randomized double-blind trial [abstract 197]. In: 3rd Conference on Retroviruses and Opportunistic Infections: program and abstracts (Washington, DC). Alexandria, VA: Infectious Diseases Society of America, 1996.
7. Bartlett JA, Benoit SL, Johnson V, et al. Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. Ann Intern Med 1996;124:161-72.
8. BC Centre for Excellence in HIV/AIDS. Therapeutic guidelines for the treatment of HIV/AIDS and related conditions. Vancouver, BC: BC Centre for Excellence in HIV/AIDS, 1996.
9. World Health Organization. Acquired immune deficiency syndrome (AIDS): interim proposal for a WHO staging system for HIV infection and disease. Wkly Epidemol Rec 1990;65:221-8.
10. Centers for Disease Control. Leads from the MMWR: revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. JAMA 1987;258:1143-54.
11. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1996: recommendations of an international panel. JAMA 1996;276:146-54.
12. Neave HR, Worthington PL. Distribution-free tests. London: Routledge, 1998.
13. Hogg RS, O'Shaughnessy MV, Gataric N, et al. AIDS death rates decline as a result of the availability of new antiretrovirals. Lancet 1997;349:1294.
14. Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998;279:450-4.
15. Graham NH, Hoover DR, Park LP, et al. Survival in HIV-infected patients who have received zidovudine: comparison of combination therapy with sequential monotherapy and continued zidovudine monotherapy. Ann Intern Med 1996;124:1031-8.